Biotech | January 03, 2022
Novavax submits data to U.S. FDA for Covid-19 EUA
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
A toll-free helpline to be set up to help doctors and patients
The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
Oravax's oral VLP vaccine in development targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the Covid-19 virus
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
The glucometer connects to one’s smartphone and provides actionable diagnostic information
Subscribe To Our Newsletter & Stay Updated
